Overview
Portfolio
More
Samsara BioCapital
Palo Alto, United States
Samsara BioCapital partners with scientific founders and entrepreneurs to translate cutting‑edge science into transformative medicines. They focus on companies developing innovative, differentiated therapies that address...
Portfolio
70+
Employees
30+
Founded
2016
AUM
≈ $1.4B
Investment focus
Stages
No stages listed
Industries
Biotechnology
Geographic scope
United States
Fund details
Funds
Fund
Vintage 2018 • $310.0M
SMSR B1, L.P.
$80.5M
Samsara Biocapital, L.P.
$1.4B
565 SPV I, L.P.
$39.3K
Sources
Samsara BioCapital
Samsara BioCapital partners with scientific founders and entrepreneurs to translate cutting‑edge science into transformative medicines. They focus on companies developing innovative, differentiated therapies that address unmet medical needs, providing long‑term capital and hands‑on support throughout the full risk cycle.
Portfolio
70+
Employees
30+
Founded
2016
AUM
≈ $1.4B
Funds
Fund · Vintage 2018 • $310.0M
SMSR B1, L.P. · $80.5M
Samsara Biocapital, L.P. · $1.4B
565 SPV I, L.P. · $39.3K
Stages
No stages listed
Industries
Biotechnology
Geographic scope
United States
Sources
Showing 24 of 49 matched portfolio companies
A2 Biotherapeutics develops Tmod™, a precision-targeting T cell therapy platform that distinguishes solid tumors from normal cells by exploiting specific gene losses unique to cancer cells. This approach addresses the challenge of effective treatment for solid tumors while minimizing damage to healthy tissue.
Funding: $352.9M
Rough estimate of the amount of funding raised
Funding: $352.9M
Rough estimate of the amount of funding raised
Abatatx offers a managed WordPress hosting service that automates domain verification, DNS configuration, and account provisioning to prevent common setup errors. The platform provides guided onboarding, real‑time support, and monitoring alerts, enabling small to medium businesses and individual site owners to launch and maintain WordPress sites with minimal downtime and technical effort.
Funding: $110.3M
Rough estimate of the amount of funding raised
Bristol-Myers Squibb
Bristol-Myers Squibb
Funding: $110.3M
Rough estimate of the amount of funding raised
The startup develops immunomodulatory therapeutics that target autoimmunity and cancer by utilizing proprietary transcription data analysis to identify key immune system compartments. This approach enables healthcare professionals to tailor treatment plans for more effective patient outcomes.
40+
2K+Approximate amount of employees
Funding: $207.3M
Rough estimate of the amount of funding raised
Bain Capital Life SciencesRedmile Group
Bain Capital Life SciencesRedmile Group
Funding: $207.3M
Rough estimate of the amount of funding raised
Abivax is developing obefazimod, an orally administered small molecule that enhances the expression of miR-124 to stabilize immune responses in patients with chronic inflammatory diseases. This approach aims to restore homeostatic levels of cytokines and chemokines, addressing the dysregulated inflammation seen in conditions like ulcerative colitis and rheumatoid arthritis.
Funding: $163.5M
Rough estimate of the amount of funding raised
Claret Capital PartnersHeights Capital Management
Claret Capital PartnersHeights Capital Management
Funding: $163.5M
Rough estimate of the amount of funding raised
ACELYRIN is a late-stage clinical biopharma company focused on the development of therapies targeting unmet medical needs in immunology, specifically through the advancement of izokibep and lonigutamab for conditions like non-infectious non-anterior uveitis and thyroid eye disease. By accelerating the clinical trials and commercialization processes, ACELYRIN aims to deliver transformative treatments that improve patient outcomes and quality of life.
Funding: $300.0M
Rough estimate of the amount of funding raised
Access Biotechnology
Access Biotechnology
Funding: $300.0M
Rough estimate of the amount of funding raised
Alamar Biosciences develops NULISA™ technology, which enables the detection of protein biomarkers from a single liquid biopsy sample with attomolar sensitivity and a dynamic range of up to 12 logs. This technology addresses the challenge of early disease diagnosis by providing researchers with a high-throughput platform for profiling clinically relevant biomarkers across various diseases, including cancer and neurodegenerative disorders.
Funding: $308.0M
Rough estimate of the amount of funding raised
Alzheimer's Drug Discovery Foundation
Alzheimer's Drug Discovery Foundation
Funding: $308.0M
Rough estimate of the amount of funding raised
Alpha9 Theranostics develops peptide-based radiopharmaceuticals for the targeted treatment of solid and hematologic malignancies. Their technology aims to improve therapeutic precision and efficacy, addressing the limitations of conventional cancer therapies.
This company develops a minimally invasive surgical device that uses photodynamic therapy to treat aggressive brain tumors. Their device delivers light to cancer cells exposed to a photosensitizer, offering patients a less invasive alternative to traditional brain surgery.
5+
500+Approximate amount of employees
Funding: $52.0M
Rough estimate of the amount of funding raised
HealthQuest CapitalSamsara BioCapital
HealthQuest CapitalSamsara BioCapital
Funding: $52.0M
Rough estimate of the amount of funding raised
Arcellx develops cell therapies utilizing its proprietary D-Domain technology and ddCAR platform to enhance the efficacy of immune cell treatments for cancer. The company targets relapsed or refractory multiple myeloma, aiming to provide patients with durable responses through its innovative CART-ddBCMA therapy.
100+
10K+Approximate amount of employees
Funding: $200.0M
Rough estimate of the amount of funding raised
Kite Pharma
Kite Pharma
Funding: $200.0M
Rough estimate of the amount of funding raised
Basecamp Bio develops cell and gene therapies using proprietary technologies such as gene editing, RNA engineering, and viral delivery systems to create effective treatments for various diseases. The company addresses the need for efficient manufacturing and development processes in the regenerative medicine sector, enabling faster access to life-saving therapies.
Funding: $1.0M
Rough estimate of the amount of funding raised
Matrix Capital Management
Matrix Capital Management
Funding: $1.0M
Rough estimate of the amount of funding raised
BE Therapeutics is engineering precursor tissue that mimics embryonic brain tissue to replace damaged neocortical and spinal cord tissue, facilitating normal maturation and integration post-transplantation. This technology aims to restore lost functions in individuals affected by stroke, trauma, neurodegeneration, and aging, addressing the current lack of effective treatments for central nervous system damage.
CARGO Therapeutics is developing tri-specific CAR T-cell therapies designed to target and eliminate B-cell lymphoma cells effectively. This approach aims to provide patients with potentially curative treatment options that traditional therapies may not achieve.
Funding: $110.0M
Rough estimate of the amount of funding raised
Funding: $110.0M
Rough estimate of the amount of funding raised
Chinook Therapeutics develops targeted therapeutics that focus on addressing significant disease burdens, particularly in kidney diseases. By utilizing advanced biological research and technology, the company aims to enhance patient outcomes and extend life expectancy.
The startup develops a healthcare platform that utilizes clinical intelligence and decision support tools to enhance patient care quality and operational efficiency. By integrating remote patient monitoring, the platform enables healthcare organizations to make informed decisions within clinical workflows, ultimately improving patient outcomes.
Funding: $11.0M
Rough estimate of the amount of funding raised
Funding: $11.0M
Rough estimate of the amount of funding raised
Delfi Diagnostics utilizes the DELFI method, which employs advanced machine learning and next-generation sequencing to analyze cell-free DNA fragments from non-invasive blood samples for early cancer detection. This approach enhances the identification of previously unrecognized cancer-associated DNA fragments, addressing the limitations of existing liquid biopsy methods that rely solely on known mutations.
Funding: $431.6M
Rough estimate of the amount of funding raised
DFJ Growth
DFJ Growth
Funding: $431.6M
Rough estimate of the amount of funding raised
Dewpoint Therapeutics is developing a drug platform that targets biomolecular condensates, which are implicated in the dysregulation of complex diseases. By integrating AI with advanced experimental technologies, the company aims to create therapies for conditions previously considered undruggable.
Funding: $286.2M
Rough estimate of the amount of funding raised
Funding: $286.2M
Rough estimate of the amount of funding raised
The startup develops immunotherapy technologies that utilize tumor-specific antigens derived from endogenous retroviral DNA sequences to enhance cancer treatment efficacy. This approach enables hospitals to accurately assess tumor specificity and immunogenic potential, improving cancer monitoring and management.
50+
7K+Approximate amount of employees
Funding: $82.6M
Rough estimate of the amount of funding raised
M VenturesPfizer Venture Investments
M VenturesPfizer Venture Investments
Funding: $82.6M
Rough estimate of the amount of funding raised
Develops first-in-class covalent protein therapeutics using a proprietary synthetic biology platform that incorporates unnatural amino acids to create irreversibly binding "War-Lock" biologics. This approach improves target modulation, reduces off-target effects, and enables sustained therapeutic efficacy with minimal systemic exposure, addressing limitations of traditional protein drugs in treating cancer and other serious diseases.
Funding: $161.0M
Rough estimate of the amount of funding raised
J.P. Morgan Asset Management
J.P. Morgan Asset Management
Funding: $161.0M
Rough estimate of the amount of funding raised
Exo Therapeutics utilizes its ExoSight™ platform to identify and develop small molecule inhibitors targeting exosites on enzymes involved in oncology and inflammation. This approach aims to enhance the modulation of enzyme activity, addressing the challenge of drugging previously inaccessible targets.
Funding: $102.8M
Rough estimate of the amount of funding raised
Funding: $102.8M
Rough estimate of the amount of funding raised
Eyebiotech is a clinical-stage biotechnology company developing therapies that target the Wnt signaling pathway to treat retinal diseases, addressing the limitations of existing treatments that often fail to improve vision or provide long-term solutions. Their lead asset, Restoret, aims to protect and restore vision for patients suffering from conditions like age-related macular degeneration and diabetic macular edema.
Fluent Biosciences offers PIPseq™, a technology that enables single-cell RNA sequencing without complex microfluidic instrumentation, allowing for the rapid and sensitive analysis of individual cells. This approach addresses the challenges of high ambient RNA background and sequencing bias, providing researchers with a cost-effective and scalable solution for diverse applications in cancer, immunology, and neuroscience.
Founded 2018
This company offers mobile diagnostic labs that can be rapidly deployed to any healthcare setting. Their system performs a wide range of tests on-site, delivering results in under 30 minutes, while more complex tests are handled by a central lab, improving patient care and reducing healthcare resource utilization.
75+
7K+Approximate amount of employees
Funding: $13.0M
Rough estimate of the amount of funding raised
Funding: $13.0M
Rough estimate of the amount of funding raised
HilleVax is developing novel vaccines targeting norovirus, which is responsible for over 90% of epidemic non-bacterial gastroenteritis outbreaks and leads to approximately 200,000 deaths annually. The company's focus on vaccine commercialization aims to mitigate the significant global economic burden of norovirus, estimated at $60.3 billion each year.
Funding: $100.0M
Rough estimate of the amount of funding raised
Funding: $100.0M
Rough estimate of the amount of funding raised
ImmunOs Therapeutics develops bispecific antibody immunotherapies that direct a patient’s immune system to target cancer cells and inflammatory disease antigens. Their lead candidate, IOS‑1002, combines engineered binding domains and an optimized Fc region to enhance specificity, potency, and half‑life, and is currently in Phase 1 trials, including combination studies with checkpoint inhibitors. The platform aims to provide pharmaceutical partners and clinicians with next‑generation, combination‑ready treatments for solid tumors and rheumatic diseases.
Funding: $11.0M
Rough estimate of the amount of funding raised
+ 3 Other investorsDouble Point Ventures
+ 3 Other investorsDouble Point Ventures
Funding: $11.0M
Rough estimate of the amount of funding raised
Showing 12 of 21 unmatched portfolio companies
Intercept Pharmaceuticals, Inc.
interceptpharma.comWe don't have a full profile for this company yet.